Publication:
Strategies for controlled ovarian stimulation in the setting of ovarian aging

dc.contributor.coauthorSeli, Emre
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorAta, Mustafa Barış
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-10T00:12:15Z
dc.date.issued2015
dc.description.abstractIn the context of assisted reproduction, the term ovarian aging is often used to refer to declining potential of ovaries to produce oocytes in adequate number or quality in response to controlled ovarian stimulation (COS). Different aspects of COS have been modified with the intention to increase the number and quality of oocytes obtained for in vitro fertilization. In the setting of ovarian aging, suppression of the luteinizing hormone (LH) surge with gonadotropin-releasing hormone (GnRH) antagonist or short GnRH agonist protocol and stimulation with a daily gonadotropin dosage of300 IU/day seem to be appropriate first choices, and there is a strong need for well-designed randomized controlled trials investigating effects of addition of LH activity, estradiol priming, transdermal testosterone administration, and growth hormone supplementation. Given the lack of high-quality evidence showing effectiveness of one approach over another, other factors such as duration of stimulation, total gonadotropin consumption and cost of medication, patient friendliness, and possible side effect profiles must be considered in tailoring the COS protocol according to each individual's needs and desires.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue6
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipNational Institute of Health (NIH) [R01 HD059909]
dc.description.sponsorshipEUNICE KENNEDY SHRIVER NATIONAL INSTITUTE of CHILD HEALTH & HUMAN DEVELOPMENT [R01HD059909] Funding Source: NIH RePORTER E. S. was supported by a grant from the National Institute of Health (NIH) (R01 HD059909). The content of the article is solely the responsibility of the authors and do not necessarily represent the official view of the NIH.
dc.description.volume33
dc.identifier.doi10.1055/s-0035-1567818
dc.identifier.eissn1526-4564
dc.identifier.issn1526-8004
dc.identifier.scopus2-s2.0-84951567023
dc.identifier.urihttps://doi.org/10.1055/s-0035-1567818
dc.identifier.urihttps://hdl.handle.net/20.500.14288/17625
dc.identifier.wos367179800011
dc.keywordsAssisted reproductive techniques
dc.keywordsOvarian reserve
dc.keywordsOvarian stimulation
dc.keywordsIn vitro fertilization
dc.keywordsPoor response
dc.keywordsDecreased ovarian reserve In-vitro fertilization
dc.keywordsRandomized controlled-trial
dc.keywordsAssisted reproductive technology
dc.keywordsPoor-responder patients
dc.keywordsRecombinant luteinizing-hormone
dc.keywordsGNRH antagonist protocol
dc.keywordsGrowth-hormone
dc.keywordsGonadotropin stimulation
dc.keywordsDouble-blind
dc.keywordsCorifollitropin alpha
dc.language.isoeng
dc.publisherThieme Medical Publ Inc
dc.relation.ispartofSeminars In Reproductive Medicine
dc.subjectObstetrics
dc.subjectGynecology
dc.subjectReproductive biology
dc.titleStrategies for controlled ovarian stimulation in the setting of ovarian aging
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorAta, Mustafa Barış
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files